{'52WeekChange': -0.4646154,
 'SandP52WeekChange': 0.0644362,
 'address1': '83 Clemenceau Avenue',
 'address2': 'No. 12-03 UE Square',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.85,
 'askSize': 800,
 'averageDailyVolume10Day': 143400,
 'averageVolume': 119725,
 'averageVolume10days': 143400,
 'beta': 1.609261,
 'beta3Year': None,
 'bid': 1.74,
 'bidSize': 900,
 'bookValue': -0.23,
 'category': None,
 'circulatingSupply': None,
 'city': 'Singapore',
 'companyOfficers': [],
 'country': 'Singapore',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.8,
 'dayLow': 1.7096,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 66104328,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '65 6225 2419',
 'fiftyDayAverage': 1.9059714,
 'fiftyTwoWeekHigh': 8.18,
 'fiftyTwoWeekLow': 0.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 36904072,
 'forwardEps': -0.5,
 'forwardPE': -3.52,
 'fromCurrency': None,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.08682,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aslanpharma.com',
 'longBusinessSummary': 'ASLAN Pharmaceuticals Limited operates as a '
                        'clinical-stage oncology and inflammatory disease '
                        'focused biopharmaceutical company in the United '
                        'States. It targets diseases that are prevalent in '
                        'Asia, and orphan indications in the United States and '
                        "Europe. The company's lead program, varlitinib, is a "
                        'reversible small molecule pan-human epidermal growth '
                        'factor receptor (HER), inhibitor that targets the '
                        'human epidermal growth factor receptors HER1, and '
                        'HER2, as well as gastric cancer. Its Varlitinib '
                        'completed a pivotal clinical trial for biliary tract '
                        'cancer. In addition, the company is developing '
                        'ASLAN003, an orally active potent inhibitor of human '
                        'dihydroorotate dehydrogenase that is in Phase II '
                        'clinical trials to treat acute myeloid leukemia; and '
                        'ASLAN004, an interleukin 4/interleukin 13 receptor '
                        'antibody for the treatment of severe atopic '
                        'dermatitis and asthma. Further, the company has '
                        'rights to develop, manufacture, and commercialize '
                        'varlitnib for all human and animal therapeutic, '
                        'diagnostic, and prophylactic uses. ASLAN '
                        'Pharmaceuticals Limited has licensing agreement with '
                        'Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai '
                        'Pharm Co., Ltd., and BioGenetics Co. Ltd.; and '
                        'licensing and research collaboration agreement with '
                        'Nanyang Technological University. The company was '
                        'founded in 2010 and is headquartered in Singapore.',
 'longName': 'ASLAN Pharmaceuticals Limited',
 'market': 'us_market',
 'marketCap': 35771648,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_419159771',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1593475200,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.76,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '65 6222 4235',
 'previousClose': 1.81,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.8,
 'regularMarketDayLow': 1.7096,
 'regularMarketOpen': 1.76,
 'regularMarketPreviousClose': 1.81,
 'regularMarketPrice': 1.76,
 'regularMarketVolume': 66476,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37991000,
 'sharesPercentSharesOut': 0.0007,
 'sharesShort': 28034,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11476,
 'shortName': 'ASLAN Pharmaceuticals Limited',
 'shortPercentOfFloat': None,
 'shortRatio': 0.2,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ASLN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.24,
 'twoHundredDayAverage': 1.8003957,
 'volume': 66476,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://aslanpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '239920'}